Femasys, Inc. FEMY 深 沪
等待开盘 02-04 09:30:00 美东时间
0.5234
+0.007
+1.43%
华盛通- 最 高0.5599
- 今 开0.5382
- 成交量 88.33万股
- 最 低 0.5063
- 昨 收 0.516
- 总市值 2251.14万
- 52周最高 1.80
- 市盈率 静 --
- 换手率 2.05%
- 52周最低 0.3067
- 委 比 -89.23%
- 总股本 4301.00万
- 历史最高 13.75
- 量 比 1.38
- 振 幅 10.39%
- 历史最低 0.2479
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution
02-03 22:16
Femasys Partners With Refuah Health Center To Offer FemaSeed As First Step In Infertility Treatment Process
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health
01-13 22:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 63.6% to $3.19 during W...
2025-12-24 20:05
Femasys Receives 510(k) Clearance From FDA For FemVue Controlled Device, Diagnostic Solution For Controlled Contrast Delivery To Evaluate Fallopian Tube Status
-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency--ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc.
2025-12-18 22:16
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
Laidlaw & Co. Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $6.5
Laidlaw & Co. analyst Yale Jen initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $6.5.
2025-11-20 22:44
Femasys shares are trading higher after the company announced FDA clearance to continue enrollment in the final phase of its FINALE trial for FemBloc and entered agreements to issue $12M in notes and warrants, potentially raising up to $58M.
Femasys shares are trading higher after the company announced FDA clearance to ...
2025-11-03 21:35
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
Biomedical innovator Femasys Inc. announced the commencement of a post-market surveillance (PMS) clinical study for its CE-marked FemBloc Permanent Birth Control, aligning with the European Union Medical Device Regulation (MDR 2017/745). The study, approved by multiple Ethics Committees and conducted in compliance with ISO 14155:2020, aims to monitor safety and performance in real-world settings. FemBloc, a first-of-its-kind non-surgical solution...
2025-10-22 13:00
Femasys Meets Nasdaq Equity Requirement After Offering
Femasys ( ($FEMY) ) has issued an update. On May 19, 2025, Femasys Inc. receive...
2025-10-21 21:48
Femasys COO Daniel Currie Announces Retirement
Femasys ( ($FEMY) ) has provided an announcement. On October 13, 2025, Daniel C...
2025-10-18 05:50
